{
  "DOI": "10.1038/s41431-020-0692-y",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-020-0692-y",
  "alternative-id": [
    "692"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "10 April 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "14 June 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "30 June 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "10 July 2020"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors declare that they have no conflict of interest."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The germline \u003ci\u003eBRCA1/2\u003c/i\u003e database is approved by North Manchester Research Ethics Committee (08/H1006/77). All women included in this study provided informed verbal and/or written consent to undergo germline \u003ci\u003eBRCA1/2\u003c/i\u003e testing."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0001-8900-0645",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Flaum",
      "given": "Nicola",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Morgan",
      "given": "Robert D.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Burghel",
      "given": "George J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Bulman",
      "given": "Michael",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Clamp",
      "given": "Andrew R.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Hasan",
      "given": "Jurjees",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Mitchell",
      "given": "Claire L.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Badea",
      "given": "Doina",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Moon",
      "given": "Sarah",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Hogg",
      "given": "Martin",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Hadjiyiannakis",
      "given": "Dennis",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Clancy",
      "given": "Tara",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Schlecht",
      "given": "Helene",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-6297-2855",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Woodward",
      "given": "Emma R.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Crosbie",
      "given": "Emma J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Edmondson",
      "given": "Richard J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wallace",
      "given": "Andrew J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Jayson",
      "given": "Gordon C.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Lalloo",
      "given": "Fiona I.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0001-6625-7739",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Harkness",
      "given": "Elaine F.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-8482-5784",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Evans",
      "given": "D. Gareth R.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2020,
        7,
        10
      ]
    ],
    "date-time": "2020-07-10T13:03:38Z",
    "timestamp": 1594386218000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        20
      ]
    ],
    "date-time": "2023-05-20T21:02:16Z",
    "timestamp": 1684616536000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        13
      ]
    ],
    "date-time": "2024-03-13T09:00:53Z",
    "timestamp": 1710320453949
  },
  "is-referenced-by-count": 21,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "11",
  "issued": {
    "date-parts": [
      [
        2020,
        7,
        10
      ]
    ]
  },
  "journal-issue": {
    "issue": "11",
    "published-print": {
      "date-parts": [
        [
          2020,
          11
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://www.springer.com/tdm",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            7,
            10
          ]
        ],
        "date-time": "2020-07-10T00:00:00Z",
        "timestamp": 1594339200000
      }
    },
    {
      "URL": "https://www.springer.com/tdm",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            7,
            10
          ]
        ],
        "date-time": "2020-07-10T00:00:00Z",
        "timestamp": 1594339200000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/s41431-020-0692-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0692-y",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0692-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1541-1547",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2020,
        7,
        10
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2020,
        7,
        10
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2020,
        11
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3322/caac.21492",
      "author": "F Bray",
      "doi-asserted-by": "crossref",
      "first-page": "394",
      "journal-title": "CA Cancer J Clin.",
      "key": "692_CR1",
      "unstructured": "Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.",
      "volume": "68",
      "year": "2018"
    },
    {
      "key": "692_CR2",
      "unstructured": "Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. 4th ed. International Agency for Research on Cancer (IARC); 2014."
    },
    {
      "DOI": "10.1016/S0140-6736(18)32552-2",
      "author": "S Lheureux",
      "doi-asserted-by": "publisher",
      "first-page": "1240",
      "journal-title": "Lancet.",
      "key": "692_CR3",
      "unstructured": "Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240–53.",
      "volume": "393",
      "year": "2019"
    },
    {
      "key": "692_CR4",
      "unstructured": "NCCN. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in ovarian cancer. 2020. https://www.nccn.org/."
    },
    {
      "DOI": "10.1093/annonc/mdt333",
      "author": "JA Ledermann",
      "doi-asserted-by": "publisher",
      "first-page": "vi24",
      "issue": "Suppl 6",
      "journal-title": "Ann Oncol.",
      "key": "692_CR5",
      "unstructured": "Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32.",
      "volume": "24",
      "year": "2013"
    },
    {
      "DOI": "10.1056/NEJMoa1909707",
      "author": "RL Coleman",
      "doi-asserted-by": "publisher",
      "first-page": "2403",
      "journal-title": "N Engl J Med.",
      "key": "692_CR6",
      "unstructured": "Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;385:2403–15.",
      "volume": "385",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1910962",
      "author": "A Gonzalez-Martin",
      "doi-asserted-by": "publisher",
      "first-page": "2391",
      "journal-title": "N. Engl J Med.",
      "key": "692_CR7",
      "unstructured": "Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl J Med. 2019;381:2391–402.",
      "volume": "381",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1810858",
      "author": "K Moore",
      "doi-asserted-by": "publisher",
      "first-page": "2495",
      "journal-title": "N Engl J Med.",
      "key": "692_CR8",
      "unstructured": "Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505.",
      "volume": "379",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S0140-6736(17)32440-6",
      "author": "RL Coleman",
      "doi-asserted-by": "publisher",
      "first-page": "1949",
      "journal-title": "Lancet.",
      "key": "692_CR9",
      "unstructured": "Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.",
      "volume": "390",
      "year": "2017"
    },
    {
      "DOI": "10.1056/NEJMoa1611310",
      "author": "MR Mirza",
      "doi-asserted-by": "publisher",
      "first-page": "2154",
      "journal-title": "N Engl J Med.",
      "key": "692_CR10",
      "unstructured": "Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64.",
      "volume": "375",
      "year": "2016"
    },
    {
      "DOI": "10.1016/S1470-2045(17)30469-2",
      "author": "E Pujade-Lauraine",
      "doi-asserted-by": "publisher",
      "first-page": "1274",
      "journal-title": "Lancet Oncol.",
      "key": "692_CR11",
      "unstructured": "Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.19.02745",
      "author": "RT Penson",
      "doi-asserted-by": "publisher",
      "first-page": "1164",
      "journal-title": "J Clin Oncol.",
      "key": "692_CR12",
      "unstructured": "Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA III, Bidzinski M, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164–74.",
      "volume": "38",
      "year": "2020"
    },
    {
      "DOI": "10.1016/S1470-2045(16)30559-9",
      "author": "EM Swisher",
      "doi-asserted-by": "publisher",
      "first-page": "75",
      "journal-title": "Lancet Oncol.",
      "key": "692_CR13",
      "unstructured": "Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1016/S1470-2045(19)30029-4",
      "author": "KN Moore",
      "doi-asserted-by": "publisher",
      "first-page": "636",
      "journal-title": "Lancet Oncol.",
      "key": "692_CR14",
      "unstructured": "Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636–48.",
      "volume": "20",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.cell.2018.03.039",
      "author": "KL Huang",
      "doi-asserted-by": "publisher",
      "first-page": "355",
      "journal-title": "Cell.",
      "key": "692_CR15",
      "unstructured": "Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173:355–70.e14.",
      "volume": "173",
      "year": "2018"
    },
    {
      "DOI": "10.1038/nature10166",
      "author": "Cancer Genome Atlas Research Network.",
      "doi-asserted-by": "publisher",
      "first-page": "609",
      "journal-title": "Nature.",
      "key": "692_CR16",
      "unstructured": "Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.",
      "volume": "474",
      "year": "2011"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-105140",
      "author": "B Rahman",
      "doi-asserted-by": "publisher",
      "first-page": "195",
      "journal-title": "J Med Genet.",
      "key": "692_CR17",
      "unstructured": "Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, et al. Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet. 2019;56:195–8.",
      "volume": "56",
      "year": "2019"
    },
    {
      "DOI": "10.1136/jmedgenet-2016-103902",
      "author": "I Plaskocinska",
      "doi-asserted-by": "publisher",
      "first-page": "655",
      "journal-title": "J Med Genet.",
      "key": "692_CR18",
      "unstructured": "Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the genetic testing in epithelial ovarian cancer (GTEOC) study. J Med Genet. 2016;53:655–61.",
      "volume": "53",
      "year": "2016"
    },
    {
      "DOI": "10.1111/1471-0528.15171",
      "author": "K Rust",
      "doi-asserted-by": "publisher",
      "first-page": "1451",
      "journal-title": "BJOG",
      "key": "692_CR19",
      "unstructured": "Rust K, Spiliopoulou P, Tang CY, Bell C, Stirling D, Phang T, et al. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. BJOG. 2018;125:1451–8.",
      "volume": "125",
      "year": "2018"
    },
    {
      "DOI": "10.1038/srep29506",
      "author": "A George",
      "doi-asserted-by": "publisher",
      "journal-title": "Sci Rep.",
      "key": "692_CR20",
      "unstructured": "George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:29506.",
      "volume": "6",
      "year": "2016"
    },
    {
      "DOI": "10.1200/JCO.2017.76.2781",
      "author": "N Colombo",
      "doi-asserted-by": "publisher",
      "first-page": "1300",
      "journal-title": "J Clin Oncol.",
      "key": "692_CR21",
      "unstructured": "Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, et al. Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. J Clin Oncol. 2018;36:1300–7.",
      "volume": "36",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.ygyno.2017.01.030",
      "author": "M Kentwell",
      "doi-asserted-by": "publisher",
      "first-page": "130",
      "journal-title": "Gynecol Oncol.",
      "key": "692_CR22",
      "unstructured": "Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, et al. Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017;145:130–6.",
      "volume": "145",
      "year": "2017"
    },
    {
      "DOI": "10.1136/jmedgenet-2018-105792",
      "author": "RD Morgan",
      "doi-asserted-by": "publisher",
      "first-page": "301",
      "journal-title": "J Med Genet.",
      "key": "692_CR23",
      "unstructured": "Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, et al. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. J Med Genet. 2019;56:301–7.",
      "volume": "56",
      "year": "2019"
    },
    {
      "DOI": "10.1038/gim.2015.30",
      "author": "S Richards",
      "doi-asserted-by": "crossref",
      "first-page": "405",
      "journal-title": "Genet Med.",
      "key": "692_CR24",
      "unstructured": "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104584",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "674",
      "journal-title": "J Med Genet.",
      "key": "692_CR25",
      "unstructured": "Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families. J Med Genet. 2017;54:674–81.",
      "volume": "54",
      "year": "2017"
    },
    {
      "DOI": "10.1093/nar/gnf056",
      "author": "JP Schouten",
      "doi-asserted-by": "publisher",
      "first-page": "e57",
      "journal-title": "Nucleic Acids Res.",
      "key": "692_CR26",
      "unstructured": "Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.",
      "volume": "30",
      "year": "2002"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104584",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "674",
      "journal-title": "J Med Genet.",
      "key": "692_CR27",
      "unstructured": "Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families. J Med Genet. 2017;54:674–81.",
      "volume": "54",
      "year": "2017"
    },
    {
      "DOI": "10.1136/jmg.2003.017996",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "474",
      "journal-title": "J Med Genet.",
      "key": "692_CR28",
      "unstructured": "Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41:474–80.",
      "volume": "41",
      "year": "2004"
    },
    {
      "DOI": "10.1200/JCO.2011.39.8545",
      "author": "K Alsop",
      "doi-asserted-by": "publisher",
      "first-page": "2654",
      "journal-title": "J Clin Oncol.",
      "key": "692_CR29",
      "unstructured": "Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654–63.",
      "volume": "30",
      "year": "2012"
    },
    {
      "DOI": "10.1093/hmg/ddu172",
      "author": "H Song",
      "doi-asserted-by": "publisher",
      "first-page": "4703",
      "journal-title": "Hum Mol Genet.",
      "key": "692_CR30",
      "unstructured": "Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23:4703–9.",
      "volume": "23",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.ejca.2019.10.018",
      "author": "N Flaum",
      "doi-asserted-by": "publisher",
      "first-page": "88",
      "journal-title": "Eur J Cancer.",
      "key": "692_CR31",
      "unstructured": "Flaum N, Crosbie EJ, Woodward ER, Lalloo F, Evans DGR. Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants. Eur J Cancer. 2020;124:88–90.",
      "volume": "124",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10897-018-0261-5",
      "author": "S Wright",
      "doi-asserted-by": "publisher",
      "first-page": "1459",
      "journal-title": "J Genet Couns.",
      "key": "692_CR32",
      "unstructured": "Wright S, Porteous M, Stirling D, Lawton J, Young O, Gourley C, et al. Patients’ views of treatment-focused genetic testing (TFGT): some lessons for the mainstreaming of BRCA1 and BRCA2 testing. J Genet Couns. 2018;27:1459–72.",
      "volume": "27",
      "year": "2018"
    }
  ],
  "reference-count": 32,
  "references-count": 32,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-020-0692-y"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "28"
}